Core Viewpoint - 康方生物's innovative drug, Ivoris monoclonal antibody, is set to release overseas Phase III clinical data mid-year, which could lead to FDA submission and increased international market revenue [1][2] Financial Performance - 康方生物 reported over 2 billion yuan in new drug sales for 2024, marking a 25% year-on-year increase, a record high [2] - Despite the sales growth, the company is projected to incur a loss of 500 million yuan in 2024 as its core drugs, Cardunil and Ivoris, will only be included in the national medical insurance directory by the end of 2024 [2] Drug Development and Market Potential - Ivoris monoclonal antibody has shown significant potential in treating various cancers, including lung cancer, and outperformed Merck's Keytruda in a head-to-head trial [2] - The partnership with Summit Therapeutics for Ivoris has resulted in a 5 billion [2] - Goldman Sachs predicts that Ivoris could reshape the 53 billion by 2041 [2]
康方生物重磅药物海外临床数据年中有望公布,抢占900亿美元肿瘤药市场